论文部分内容阅读
多药耐药(MDR)是急性白病化疗失败的主要原因,其机制较复杂,而由多药耐药基因(mdr-1)编码的P_(170)的过度表达所介导的耐药是主要的途径。CD_(34)抗原是目前公认表达于干细胞或造血祖细胞的一种分化抗原,急性髓细胞白血病(AML)患者白血病细胞CD_(34)抗原表达明显增加,且与化疗效果负相关。为探讨P_(170)和CD_(34_)两种不同的膜蛋白在白血病临床耐药中的作用和相互联系,我们应用免疫细胞化学APAAP法检测了急性白血病P_(170)和CD_(34),结果分析如下。 1 材料和方法 1.1 检测对象:47例AML患者均为我所初治
Multidrug resistance (MDR) is the main cause of chemotherapy failure in acute white disease, and its mechanism is more complex. Drug resistance mediated by overexpression of P_(170) encoded by multidrug resistance gene (mdr-1) is The main way. The CD_(34) antigen is a differentiation antigen currently recognized in stem cells or hematopoietic progenitor cells. The expression of CD_(34) antigen in acute myeloid leukemia (AML) patients is significantly increased and is negatively correlated with the effect of chemotherapy. In order to investigate the roles and interactions of two different membrane proteins, P 170 and CD 34 , in leukemia clinical drug resistance, we used immunocytochemistry APAAP to detect acute leukemia P 170 and CD 34 The results are analyzed as follows. 1 Materials and methods 1.1 Test subjects: 47 cases of AML patients were my initial treatment